1 week Ago By ABMN Staff
MediWound Ltd. ( NASDAQ:MDWD – Get Free Report )’s stock price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $17.
45 and traded as low as $14.77. MediWound shares last traded at $15.
35, with a volume of 130,738 shares. Wall Street Analysts Forecast Growth A number of analysts recently issued reports on MDWD shares. Craig Hallum initiated coverage on shares of MediWound in a research report on Friday, February 28th.
They set a “buy” rating and a $39.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $25.
00 price objective on shares of MediWound in a research report on Thursday, March 20th. Finally, StockNews.com upgraded shares of MediWound to a “sell” rating in a report on Friday, March 21st.
Check Out Our Latest Research Report on MediWound MediWound Trading Up 1.8 % MediWound ( NASDAQ:MDWD – Get Free Report ) last announced its earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.
36) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.23.
The business had revenue of $5.84 million during the quarter, compared to the consensus estimate of $5.79 million.
MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%.
During the same period in the prior year, the firm earned ($0.19) earnings per share. As a group, research analysts forecast that MediWound Ltd.
will post -2.66 EPS for the current year. Institutional Trading of MediWound Several hedge funds and other institutional investors have recently bought and sold shares of MDWD.
GAMMA Investing LLC lifted its holdings in MediWound by 1,507.1% in the first quarter. GAMMA Investing LLC now owns 1,816 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 1,703 shares during the last quarter.
R Squared Ltd acquired a new position in shares of MediWound during the fourth quarter valued at $32,000. Russell Investments Group Ltd. raised its position in shares of MediWound by 154.
1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 1,162 shares in the last quarter.
MetLife Investment Management LLC bought a new stake in shares of MediWound in the 3rd quarter worth $89,000. Finally, Bank of America Corp DE boosted its holdings in MediWound by 38.0% during the fourth quarter.
Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 2,178 shares in the last quarter. 46.83% of the stock is owned by institutional investors.
About MediWound ( Get Free Report ) MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
See Also Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter ..
